The company also noted that patients with cirrhosis due to NASH face a bleak prognosis, as, unless they receive a transplant, only half survive beyond five years. There has been a string of failed ...

Intercept Pharma’s obeticholic acid (OCA) – trying to become the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) – will come under scrutiny by FDA advisors before the ...